Upadacitinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Upadacitinib
- Upadacitinib: From Immune-Mediated Inflammatory Disease to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
Upadacitinib: From Immune-Mediated Inflammatory Disease to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
One-Sentence Summary
Upadacitinib is a selective JAK1 inhibitor that acts through immunomodulatory and anti-inflammatory pathways; its specific approved indication is not recorded in the current dataset. The TxGNN model’s top-ranked prediction links it to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome, a rare congenital developmental disorder, but this pairing is supported by no clinical trials and no published literature, and the evidence pack’s own mechanistic review flags it as a likely knowledge-graph noise signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in current dataset (Upadacitinib is a selective JAK1 inhibitor used for immune-mediated inflammatory conditions) |
| Predicted New Indication | Colobomatous microphthalmia-rhizomelic dysplasia syndrome |
| TxGNN Prediction Score | 99.61% |
| Evidence Level | L5 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Upadacitinib is not available in this evidence pack (flagged as a High-severity data gap, DG002, pending a DrugBank API lookup). Based on information embedded in the prediction rationale itself, Upadacitinib is described as a selective JAK1 inhibitor whose therapeutic effect operates through immunomodulatory and anti-inflammatory signaling pathways.
Colobomatous microphthalmia-rhizomelic dysplasia syndrome is a rare congenital malformation syndrome affecting eye and skeletal development. It is a structural developmental disorder rather than an immune- or inflammation-driven condition, so there is no established disease-mechanism overlap with JAK1 inhibition.
The pack’s own rationale explicitly characterizes this pairing as a probable knowledge-graph noise association: TxGNN assigned it the highest raw prediction score (99.61%) among the ten candidates evaluated, yet the accompanying biological review found no reasonable link between JAK1-mediated immune modulation and a congenital structural defect. For context, other candidates further down the ranked list — plasma cell myeloma (ranks 3 and 7) and amyotrophic lateral sclerosis (rank 9) — carry more plausible mechanistic hypotheses (IL-6/JAK/STAT3 signaling in myeloma progression; JAK-STAT-driven neuroinflammation in ALS) and were classified as “Research Question” rather than “Hold,” although they too currently lack any clinical or literature evidence.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
No EU marketing authorizations are currently recorded for Upadacitinib in this dataset (0 authorizations; market status: not marketed).
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: TxGNN assigns a high raw score to this pairing, but there is no clinical trial or literature evidence, and the accompanying mechanistic review concludes the association is likely a knowledge-graph noise signal with no biological plausibility linking JAK1 inhibition to a congenital structural malformation syndrome.
To proceed, the following is needed:
- Resolve DG001 (TFDA/EMA label warnings and contraindications) and DG002 (confirmed mechanism of action via DrugBank API) before any safety evaluation (S1) can begin
- Confirmed original indication and EU marketing authorization data for Upadacitinib
- If further repurposing research is pursued, prioritize the mechanistically more plausible “Research Question” candidates in this pack (plasma cell myeloma, amyotrophic lateral sclerosis) over this top-ranked but biologically implausible pairing
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.